Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.
Alexis LeVeeMegan WongSarah FloresNora RuelHeather McArthurJames WaismanJoanne MortimerPublished in: The oncologist (2024)
In this real-world analysis of patients with TNBC treated with NAC plus pembro, younger age and the completion of at least 8 cycles of pembrolizumab were associated with pCR.